← Oncology Approval Tracker

FDA DECISION ·

Modeyso

dordaviprone · Jazz Pharmaceuticals

Accelerated approvalNew therapyDiffuse midline glioma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children age 1 year or older with progressive H3 K27M-mutated diffuse midline glioma after prior therapy.

LAMPGEN ANALYSIS

Why it matters

The decision introduced a systemic treatment for progressive H3 K27M-mutated diffuse midline glioma on accelerated approval.

What research teams should watch

Coordinate access to molecular neuropathology, imaging review, and age-appropriate oral dosing across referral sites.

PRIMARY RECORDS

Sources